

7. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a light chain] containing the three light chain CDRs of antibody 11D10.

*sub C2*

8. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a heavy chain] containing the three heavy chain CDRs of antibody 11D10.

*2*

9. (Amended) The [isolated] polynucleotide of claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:2.

*b*

10. (Amended) The [isolated] polynucleotide of claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:4.

11. (Amended) The [isolated] polynucleotide of claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable in region encoding sequence in SEQ ID NO:1.

12. (Amended) The [isolated] polynucleotide of claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable region encoding sequence in SEQ ID NO:3.

*3*

14. (Amended) A[n isolated] polynucleotide comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:1, said region [capable of] forming a stable duplex with a polynucleotide consisting of the light chain variable encoding sequence of SEQ ID NO:1 under hybridization conditions [where the region does not form a stable hybrid with SEQ ID NO:5 through SEQ ID NO:14] of 68°C and 0.15 M NaCl and 15 mM citrate buffer (1 X SSC).

*3*

15. (Amended) A[n isolated polynucleotide] comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:3, said region [capable of] forming a stable duplex with a polynucleotide consisting of the heavy chain variable encoding sequence of SEQ ID NO:3 under hybridization conditions [where the region does not form a stable hybrid with

*Ab C3*  
SEQ ID NO:15 through SEQ ID NO:32] of 68°C and 0.15 M NaCl and 15 mM citrate buffer  
(1 X SSC).

*Ab C3*  
16. (Amended) A polynucleotide according to claim 6, wherein the polynucleotide is a cloning vector.

*Ab C3*  
17. (Amended) A polynucleotide according to claim 6, wherein the polynucleotide is an expression vector.

*Ab C3 Ab M6 C6*  
18. (Amended) The expression vector of claim 17, wherein the expression vector is vaccinia.

*Ab C4*  
19. (Amended) A host cell comprising the polynucleotide of claim 6, wherein the polynucleotide is a recombinant polynucleotide.

*Ab C4*  
38. (Amended) A [pharmaceutical] composition comprising [an effective amount of] the polynucleotide of claim 6 and a pharmaceutically acceptable excipient.

*Ab C4*  
41. (Amended) An immunogenic composition [vaccine] comprising [an effective amount of] the polynucleotide of claim 6 and a pharmaceutically acceptable excipient.

*Ab C4*  
44. (Amended) The [vaccine] immunogenic composition of claim [38] 41, wherein the [vaccine] immunogenic composition [is] comprises a live virus or viral expression vector.

*Ab C4*  
45. (Amended) The [vaccine] immunogenic composition of claim 44, wherein the [vaccine] immunogenic composition is vaccinia.

*Ab 11D10*  
59. (New) The polynucleotide of claim 6, wherein antibody 11D10 has the light and heavy chain variable region sequences contained in ~~SEQ ID NO:2 and SEQ ID NO:4~~, respectively.

*Ab*  
60. (New) The composition of claim 38, further comprising an amount of the polynucleotide sufficient to elicit an anti-HMFG immunological response.